Drug profile

The FDA adverse-event record for Dinotefuran, Pyriproxyfen

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Dinotefuran, Pyriproxyfen. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
11.8%
death-coded share
Dog
most-reported species
3
Emesis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
2
Deaths Reported
11.8%
Death Rate

Active Ingredients

Dinotefuran, Pyriproxyfen

Administration Routes

UnknownTopical

Species Affected

Dog 14
Cat 3

Most Affected Breeds

Terrier - Yorkshire 3
Domestic Shorthair 2
Crossbred Canine/dog 1
Pinscher - Miniature 1
Schnauzer (unspecified) 1
Retriever - Golden 1
Cat (other) 1
Bulldog - French 1
Shih Tzu 1
Dachshund - Standard Smooth-haired 1

Most Reported Reactions

Emesis 3
Lack of efficacy - NOS 3
Vomiting 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Other abnormal test result NOS 2
Elevated total bilirubin 2
Elevated alanine aminotransferase (ALT) 2
Elevated bile acids 2
Hepatitis 2
Hypersalivation 2
Anaphylaxis 2
Ataxia 2

Outcome Breakdown

Ongoing
11 (64.7%)
Recovered/Normal
4 (23.5%)
Died
1 (5.9%)
Euthanized
1 (5.9%)

Dinotefuran, Pyriproxyfen Adverse Event Insights

17 reports name Dinotefuran, Pyriproxyfen; 2 recorded a death outcome (11.8% of reported events, not a population-level mortality rate). Active ingredient: Dinotefuran, Pyriproxyfen. Administration routes: Unknown, Topical.

By species: Dog (14 reports), Cat (3 reports). By breed: Terrier - Yorkshire (3), Domestic Shorthair (2), Crossbred Canine/dog (1).

Leading clinical signs: Emesis (3), Lack of efficacy - NOS (3), Vomiting (3), Lethargy (see also Central nervous system depression in 'Neurological') (2). Outcome, 17 coded reports: Ongoing leads at 64.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.